Vincent Tubiolo, MD
Allergy · Santa Barbara, CANPI 1083778864
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.
Across 399 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Octapharma USA, Inc.$960
- Regeneron Healthcare Solutions, Inc.$957
- Takeda Pharmaceuticals U.S.A., Inc.$788
- Sanofi$666
- plus $3K from 29 others
What the payments were for
- Consulting fees$551%
- Speaking & faculty fees$7507%
- Food & beverage$9,23691%
- Education$60%
- Other$1361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 127 | $2,299 |
| AstraZeneca | 41 | $1,221 |
| Octapharma USA, Inc. | 9 | $960 |
| Regeneron Healthcare Solutions, Inc. | 39 | $957 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $788 |
| Sanofi | 24 | $666 |
| Novartis | 23 | $517 |
| CSL Behring | 12 | $298 |
| Pharming Healthcare, Inc. | 9 | $269 |
| Alk-abello, Inc | 7 | $213 |
| Grifols USA, LLC | 6 | $204 |
| Blueprint Medicines Corporation | 3 | $161 |
| Amgen | 6 | $150 |
| Genentech USA, Inc. | 2 | $142 |
| Welch Allyn | 1 | $136 |
| Biocryst US Sales Co., LLC | 5 | $130 |
| Shire North American Group Inc | 6 | $129 |
| Kaleo, Inc. | 5 | $115 |
| Pfizer | 5 | $114 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $104 |
| Ionis Pharmaceuticals, Inc. | 4 | $86 |
| Optinose US, Inc. | 4 | $79 |
| Bio Products Laboratory USA, Inc. | 3 | $67 |
| Greer Laboratories, Inc. | 2 | $66 |
| Mylan Specialty L.p. | 3 | $57 |
| ADMA Biomanufacturing LLC | 3 | $55 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Incyte Corporation | 2 | $34 |
| Merck | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Organon | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,183 in reported general payments places this provider in the 75th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $288,714 |
| Dupixent SyringeDupilumab | 63 | $253,243 |
| XolairOmalizumab | 67 | $206,983 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $105,402 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $102,252 |
| TezspireTezepelumab-Ekko | 18 | $76,785 |
| Dupixent PenDupilumab | 16 | $59,711 |
| Spiriva RespimatTiotropium Bromide | 43 | $26,843 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $24,158 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $15,751 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $12,102 |
| Ipratropium Bromide | 190 | $6,388 |
| Qvar RedihalerBeclomethasone Dipropionate | 18 | $5,635 |
| Azelastine Hcl | 161 | $5,403 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $5,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra, Privigen | $298 | $390,96645 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,299 | $129,559153 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,221 | $104,63979 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $5,63518 claims |
| Alk-abello, IncOdactra | $213 | $4,15912 claims |
| Hikma Pharmaceuticals USAEpinephrine | $24 | $2,36714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 allergy providers in California.
Other allergy in Santa Barbara
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
- Michelle YasharpourBeverly Hills$48K
- Stuart EpsteinBeverly Hills$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.